<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6499">
  <stage>Registered</stage>
  <submitdate>14/04/2017</submitdate>
  <approvaldate>14/04/2017</approvaldate>
  <nctid>NCT03163602</nctid>
  <trial_identification>
    <studytitle>Surgical Treatment of Peri-implantitis</studytitle>
    <scientifictitle>Surgical Treatment of Peri-implantitis. A Randomised Controlled Trial.</scientifictitle>
    <utrn />
    <trialacronym>STP</trialacronym>
    <secondaryid>15-116</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peri-Implantitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Control group
Treatment: devices - Test group

Active Comparator: Control Group 1 - Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)

Active Comparator: Test Group 2 - Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)


Treatment: drugs: Control group
Access flap and debridement

Treatment: devices: Test group
Regenerative treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>resolution of peri-implantitis - no bleeding or suppuration on probing, no further bone loss, reduction in probing depth</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>probing depth change - mm</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>radiographic bone level change - mm</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in peri-implant soft tissue level - mm</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient reported outcomes - VAS scores</outcome>
      <timepoint>1, 6, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Presence of = 1 implant with a probing depth (PD) = 5 mm with bleeding and/or suppuration
        (SUP) on probing, and peri-implant bone loss = 3mm with an intraosseous defect component</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Smokers &gt; 10 cigarettes per day

          -  Patients with uncontrolled diabetes mellitus

          -  Pregnant or lactating women (self reported)

          -  Patients with a systemic illness that preclude them from oral surgery

          -  Patients with an allergy to amoxicillin or metronidazole or chlorhexidine.

          -  Patients requiring antibiotic prophylaxis and Patients who have taken antibiotics in
             the past 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>The University of Western Australia - Perth</hospital>
    <postcode>6009 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Osteology Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this randomized controlled study is to evaluate the outcome of surgical treatment
      of peri-implantitis with and without the use of a bone substitute graft covered by a collagen
      membrane. There will be a follow up period of 12 months. Outcome measures will include
      assessments of inflammation, probing depth, recession, radiological parameters and PROMs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03163602</trialwebsite>
    <publication>Esposito M, Grusovin MG, Worthington HV. Treatment of peri-implantitis: what interventions are effective? A Cochrane systematic review. Eur J Oral Implantol. 2012;5 Suppl:S21-41. Review.
Heitz-Mayfield LJ, Mombelli A. The therapy of peri-implantitis: a systematic review. Int J Oral Maxillofac Implants. 2014;29 Suppl:325-45. doi: 10.11607/jomi.2014suppl.g5.3. Review.
Carcuac O, Derks J, Charalampakis G, Abrahamsson I, Wennström J, Berglundh T. Adjunctive Systemic and Local Antimicrobial Therapy in the Surgical Treatment of Peri-implantitis: A Randomized Controlled Clinical Trial. J Dent Res. 2016 Jan;95(1):50-7. doi: 10.1177/0022034515601961. Epub 2015 Aug 18.
Heitz-Mayfield LJ, Salvi GE, Mombelli A, Loup PJ, Heitz F, Kruger E, Lang NP. Supportive peri-implant therapy following anti-infective surgical peri-implantitis treatment: 5-year survival and success. Clin Oral Implants Res. 2016 Jun 23. doi: 10.1111/clr.12910. [Epub ahead of print]
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lisa Heitz-Mayfield, OdontDr</name>
      <address>The University of Western Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Heitz-Mayfield, Odont Dr</name>
      <address />
      <phone>(+61 0861101686)</phone>
      <fax />
      <email>heitz.mayfield@iinet.net.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>